| Defining and measuring ‘inhalant’use in population-based surveys R Crossin, J Whelan, J Ball International Journal of Drug Policy, 103991, 2023 | 4 | 2023 |
| Harm reduction behaviours and harm experiences of people who use 3, 4-methylenedioxymethamphetamine (MDMA) in Aotearoa New Zealand J Whelan, G Noller, RD Ward Harm Reduction Journal 21 (1), 67, 2024 | 2 | 2024 |
| Rolling through TikTok: An analysis of 3, 4‐methylenedioxymethamphetamine‐related content J Whelan, GE Noller, RD Ward Drug and alcohol review 43 (1), 36-44, 2024 | 2 | 2024 |
| A policy analysis of how alkyl nitrites (poppers) became prescription-only in Aotearoa New Zealand R Crossin, J Whelan, E Hughes, BB Ang International Journal of Drug Policy, 104105, 2023 | 1 | 2023 |
| A thematic analysis of MDMA-related harm and harm reduction experiences and knowledge in Aotearoa New Zealand J Whelan, RD Ward, G Noller Harm Reduction Journal 21 (1), 100, 2024 | | 2024 |
| Reported effects of psychedelic experiences on personal cognitions and beliefs in Aotearoa A Boardman, S McGruddy, E Mills, J Whelan, G Noller, R Ward DRUG AND ALCOHOL REVIEW 42, S44-S44, 2023 | | 2023 |
| 3, 4-Methylenedioxymethamphetamine use in Aotearoa: A quantitative survey exploration J Whelan, G Noller, R Ward DRUG AND ALCOHOL REVIEW 42, S186-S186, 2023 | | 2023 |
| Aotearoa MDMA Use and Users Survey J Whelan, R Ward, G Noller OSF, 2021 | | 2021 |
| Effects of Secreted Amyloid Precursor Protein-Alpha Peptide Fragments on Glutamate Receptor Subunit Trafficking in the Rat Hippocampus JDP Whelan | | 2020 |
